March 2026 in “Cleveland Clinic Journal of Medicine” This review discusses polycystic ovary syndrome and incorporates updates from a 2023 guideline, but reports no new research findings on diagnosis or management.
July 2025 in “Journal of Pharmacognosy and Phytochemistry” This review explores the potential benefits of plant-based diets, herbal remedies, and phytochemicals for managing PCOS, suggesting they may help regulate menstrual cycles, improve metabolic parameters, and reduce androgen levels, offering a promising, holistic approach to treatment.
This review discusses the diagnostic criteria and management challenges for polycystic ovarian syndrome and reports no clinical results, highlighting complications associated with pregnancy in women with the condition.
December 2015 in “University of Birmingham Institutional Research Archive (University of Birmingham)” This study showed that regulation of adipose androgen generation via AKR1C3 may contribute to a cycle of hyperinsulinaemia and lipid accumulation in women with PCOS.
February 2026 in “Editora Pasteur eBooks” This abstract does not report specific research results but introduces a book focusing on the intersection of endocrinology and aesthetic medicine and its growing importance in contemporary clinical practice.
1265 citations
,
October 2013 in “The Journal of Clinical Endocrinology and Metabolism” This guideline from the Endocrine Society recommends using the Rotterdam criteria for diagnosing polycystic ovary syndrome and outlines first-line treatments, emphasizing hormonal contraceptives and lifestyle intervention.
658 citations
,
June 2003 in “Endocrine reviews” This review discusses the role of androgens in the progression of cardiovascular disease and explores novel therapeutic targets without reporting new clinical results.
74 citations
,
July 2010 in “The Journal of Clinical Endocrinology & Metabolism” This study found that gonadal dysfunction is very common in premenopausal women with acromegaly and may be caused by hyperprolactinemia, GH/IGF-I excess, or tumor effects.
15 citations
,
April 2022 in “Ginekologia Polska” Higher thyroid hormone levels may be linked to certain types of polycystic ovary syndrome.
12 citations
,
September 2017 in “Molecular and Cellular Endocrinology” This review analyzes how androgens impact sexual desire and reproductive behaviors, emphasizing molecular interactions, but provides no new clinical results.
10 citations
,
May 2018 in “Neuropharmacology” This study suggests that inhibitors of steroidogenic enzymes may have therapeutic potential for certain behavioral disorders linked to dopaminergic hyperfunction, despite concerns about their endocrine impacts.
In this study assessing post-menopausal Asian women, distinct shifts in Malassezia species prevalence on the skin were linked to increased inflammation and impaired skin barrier function, potentially driving disorders like psoriasis and seborrheic dermatitis.
July 2015 in “Cambridge University Press eBooks” The document concludes that careful history and physical exams are crucial for accurately diagnosing polycystic ovary syndrome and distinguishing it from other similar conditions.
37 citations
,
January 2004 in “Hormone Research in Paediatrics” In this study, the prevalence of clinical polycystic ovary syndrome among high school girls in Isfahan, Iran was reported at 3%, with a note that hormonal assessments might uncover higher rates.
7 citations
,
January 2024 in “Medicinska istrazivanja” This review outlines the complexities and varied manifestations of polycystic ovary syndrome, highlighting challenges in diagnosis and management but reports no new clinical findings.
71 citations
,
November 2012 in “Expert Opinion on Drug Safety” This article reviews the reported sexual and psychological side effects of 5-alpha reductase inhibitors for benign prostatic hyperplasia, emphasizing the need for further clinical studies.
2 citations
,
January 2025 in “Medicine” This study in Saudi female patients with hyperprolactinemia found that pituitary imaging is often indicated due to a high prevalence of pituitary anomalies, with prolactin levels showing moderate accuracy in predicting adenomas and a suggested cutoff level of >38.71 ng/mL for diagnosis.
February 2023 in “Frontiers in Endocrinology” In this study, prenatal androgen exposure was linked to altered sexual behaviors in both male and female mice, with specific effects on mounting and lordosis behaviors.
2 citations
,
December 2024 in “Clinical Endocrinology” This study suggests that persistent symptoms in patients with controlled functioning adenomas may indicate a coexisting PCOS diagnosis, highlighting the need for precise differentiation and timely management of these conditions.
2 citations
,
July 2022 in “Sexual Medicine” This study found that 5-α reductase inhibitors and neuropsychiatric medications were most frequently reported for erectile dysfunction in a national pharmacovigilance database from 2010 to 2020.
This preclinical study found that finasteride withdrawal in rats caused inflammation in the gut and hypothalamus, while allopregnanolone treatment partially reduced these effects, suggesting potential therapeutic benefits for post-finasteride syndrome.
July 2025 in “Reproductive Biology and Endocrinology” This study found that early postnatal androgen activity affects the long-term expression of hormone receptors differently in female Wistar rats, influencing neural system programming during development.
7 citations
,
May 2024 in “Acta Obstetricia Et Gynecologica Scandinavica” This study found that women with PCOS and amenorrhea have a higher prevalence of insulin resistance, prediabetes, and dyslipidemia compared to those with oligomenorrhea or eumenorrhea, suggesting that menstrual dysfunction severity could be an indicator of heightened cardiometabolic risk in these women.
1 citations
,
July 2023 in “Frontiers in Immunology” This review highlights the role of chronic stress, oxidative stress, and immune processes in the development of Hashimoto’s thyroiditis and polycystic ovary syndrome, emphasizing the potential of antioxidants in their treatment based on the existing literature.
August 2025 in “Obstetrics and gynecology.” This article reviews the management of polycystic ovarian syndrome, highlighting lifestyle modification and individualized pharmacological treatment strategies, and reports no new clinical results.
November 2023 in “Frontiers in Neuroendocrinology” This study suggests that post-finasteride syndrome and post-SSRI sexual dysfunction share potential etiopathogenetic mechanisms involving brain modulators, neurotransmitters, and gut microbiota, although more research is needed to understand these conditions fully.
This study reviewed existing literature to demonstrate that thyroid disorders have a significant and underestimated impact on hair loss, highlighting gaps in current knowledge and the need for further research to better diagnose and manage hair disorders linked to thyroid dysfunction.
3 citations
,
May 2012 in “BMC Endocrine Disorders” This article presents a unique case of post-partum panhypopituitarism and autoimmune conditions in a 37-year-old woman from Africa, emphasizing the need for early diagnosis and treatment to improve outcomes in similar settings.
24 citations
,
July 2019 in “Reproductive Medicine and Biology” This review discusses the classification and treatment of ejaculatory dysfunction, outlining both pharmacotherapy and behavioral therapy as primary interventions, but does not present new clinical findings.
7 citations
,
March 2017 in “Medical Hypotheses” This study suggests that dysfunctions and altered expression of aquaporins may play a role in PCOS-related disorders, potentially impacting folliculogenesis and integrating with the insulin-dependent hypothesis of PCOS pathogenesis.